Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    dksh-m-2025-05-26

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Padeliporfin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImPact Biotech Presents Updated Padeliporfin VTP Data at AUA 2025
    ImPact Biotech Presents Updated Padeliporfin VTP Data at AUA 2025

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069134/0/en/ImPact-Biotech-Presents-Updated-Efficacy-Data-from-Evaluation-of-Padeliporfin-VTP-in-LG-UTUC-and-Intermediate-Risk-Prostate-Cancer-at-AUA-2025.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    ImPact Biotech Presents New Data on Padeliporfin VTP at AUA 2025
    ImPact Biotech Presents New Data on Padeliporfin VTP at AUA 2025

    11 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/11/3060047/0/en/ImPact-Biotech-Announces-New-Data-Presentations-at-AUA-2025-Highlighting-Safety-and-Efficacy-of-Padeliporfin-VTP.html

    GLOBENEWSWIRE
    11 Apr 2025
    Share Share
    ImPact Biotech Announces 50% Enrollment In Phase 3 Englighted Trial
    ImPact Biotech Announces 50% Enrollment In Phase 3 Englighted Trial

    27 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/27/2954460/0/en/ImPact-Biotech-Announces-50-Enrollment-in-Phase-3-ENLIGHTED-Clinical-Trial-of-Padeliporfin-VTP-in-Low-Grade-Upper-Tract-Urothelial-Cancer.html

    GLOBENEWSWIRE
    27 Sep 2024
    Share Share
    ImPact's Padeliporfin VTP Data In Low Grade Upper Tract Urothelial Cancer
    ImPact's Padeliporfin VTP Data In Low Grade Upper Tract Urothelial Cancer

    02 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/02/2891848/0/en/ImPact-Biotech-Presents-Additional-Interim-Data-from-ENLIGHTED-Study-of-Padeliporfin-VTP-in-Low-Grade-Upper-Tract-Urothelial-Cancer.html

    GLOBENEWSWIRE
    02 Jun 2024
    Share Share
    ImPact's Padeliporfin Shows Positive Phase 3 Bladder Cancer Data
    ImPact's Padeliporfin Shows Positive Phase 3 Bladder Cancer Data

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875744/0/en/ImPact-Biotech-Presents-Preliminary-Phase-3-Results-from-ENLIGHTED-Study-of-Padeliporfin-VTP-in-Low-Grade-Upper-Tract-Urothelial-Cancer.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    ImPact Biotech's Padeliporfin VTP UTUC Data at Conferences
    ImPact Biotech's Padeliporfin VTP UTUC Data at Conferences

    24 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/24/2868734/0/en/ImPact-Biotech-to-Present-Interim-Phase-3-Data-from-ENLIGHTED-Study-of-Padeliporfin-VTP-in-Low-Grade-UTUC-at-Upcoming-Medical-Conferences.html

    GLOBENEWSWIRE
    24 Apr 2024
    Share Share